Managing Product Pipeline Communications
When your company has a product in development, whether drug, device or biotech, what you can — and can’t — say about it is tightly regulated by the FDA.
At the same time, the SEC requires that information of material value to investors be properly disclosed to them.
Of course, this SEC requirement involves exactly the same products you have in your pipeline, the ones that the FDA wants you to be very careful about discussing.
This management report will tell you how to balance these seemingly contradictory demands and how to handle all the forms “communication” takes today — from tweets to talking points, from press releases to the slides investors see on a conference call. You will learn:
With Managing Product Pipeline Communications you’ll be able to confidently account for the various perspectives — regulators on both sides, investors and the general public — and ensure that the right people get the information they should from you every time.
Order Your Copy Today!